Arazlo, a topical retinoid medication containing tazarotene, is prescribed for the treatment of acne vulgaris. The elevated cost associated with this medication stems from a confluence of factors inherent to the pharmaceutical industry and the specific characteristics of the drug itself.
The price reflects substantial investment in research and development, clinical trials required for regulatory approval, and the costs associated with manufacturing and distribution. Additionally, patent protection grants the manufacturer exclusive rights, limiting competition and allowing for a higher price point during the period of exclusivity. The efficacy of the medication in treating acne, particularly moderate to severe cases, contributes to its value proposition despite the higher cost. Furthermore, compared to older retinoids, Arazlo uses a lotion formulation designed for better tolerability. This newer formulation required further research and development that contributes to the overall expense.
